The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers.
 
Dazhi Liu
Consulting or Advisory Role - InVitae
 
Vicky Makker
Consulting or Advisory Role - ArQule; Clovis Oncology; DualityBio; Eisai; Faeth Therapeutics; GlaxoSmithKline; IBM; ITeos Therapeutics; Kartos Therapeutics; Karyopharm Therapeutics; Lilly; Merck; Novartis; Takeda
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); DualityBio (Inst); Eisai (Inst); Faeth Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Eisai; Karyopharm Therapeutics; Merck
Other Relationship - IBM
 
Darren J. Buonocore
Stock and Other Ownership Interests - Merck; Novartis
 
Ronglai Shen
No Relationships to Disclose
 
Rona Yaeger
Honoraria - Zai Lab
Consulting or Advisory Role - Mirati Therapeutics
Research Funding - Array BioPharma (Inst); Boehringer Ingelheim (Inst); Mirati Therapeutics (Inst); Pfizer (Inst)
 
Michelle S. Ginsberg
No Relationships to Disclose
 
Randy Yeh
No Relationships to Disclose
 
Amanda Johnson
No Relationships to Disclose
 
Michael Offin
Honoraria - OncLive
Consulting or Advisory Role - American Society for Radiation Oncology; Jazz Pharmaceuticals; Novartis; PharmaMar; Targeted Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
David B. Solit
Stock and Other Ownership Interests - Fore Biotherapeutics; Pyramid Biosciences; Scorpion Therapeutics; Vividion Therapeutics
Consulting or Advisory Role - BridgeBio Pharma; Fog Therapeutics; Fore Biotherapeutics; Pfizer; Scorpion Therapeutics; Vividion Therapeutics
 
Alexander E. Drilon
Stock and Other Ownership Interests - Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; i3 Health; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV Mais; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bridge Medicines; Daiichi Sankyo/UCB Japan; Earli; Epizyme; Genentech/Roche; Harpoon Therapeutics; Ipsen; Jazz Pharmaceuticals; Kowa; Merck; Syros Pharmaceuticals; Syros Pharmaceuticals
Research Funding - Merck (Inst); Roche/Genentech (Inst)
 
Mark G. Kris
Consulting or Advisory Role - AstraZeneca; BerGenBio; Janssen; Merus; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Genentech
 
Jorge S. Reis-Filho
Leadership - Grupo Oncoclinicas
Stock and Other Ownership Interests - PAIGE.AI; Repare Therapeutics
Consulting or Advisory Role - Bain Capital Life Sciences; Genentech/Roche; Goldman Sachs; Invicro; Novartis; Paige.AI; Personalis; Repare Therapeutics; SAGA Diagnostics; Ventana Medical Systems; Volition RX
 
Pedram Razavi
Stock and Other Ownership Interests - Odyssey Biosciences
Honoraria - Daiichi Sankyo/Astra Zeneca; Pfizer
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Epic Sciences; Guardant Health; Guardant Health; Inivata; Natera; Novartis; PAIGE.AI; Prelude Therapeutics; SAGA Diagnostics; Tempus
Research Funding - Archer (Inst); AstraZeneca (Inst); AstraZeneca (Inst); bioTheranostics (Inst); Epic Sciences (Inst); GRAIL (Inst); Guardant Health (Inst); Illumina (Inst); Novartis (Inst); Tempus (Inst)
 
Sarat Chandarlapaty
Stock and Other Ownership Interests - Odyssey Biosciences; Totus Medicines
Consulting or Advisory Role - AstraZeneca/MedImmune; Boxer Capital; Inivata; Lilly; Novartis; Paige.ai; Prelude Therapeutics; SAGA Diagnostics; Sanofi
Research Funding - Ambryx (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Paige.ai (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for (1) targeting mutant ER with ER PROTACS and (2) targeting CDK4/6 with CDK4/6 PROTACS (Inst)
Travel, Accommodations, Expenses - Novartis Institutes for BioMedical Research
Other Relationship - Peerview; Targeted Oncology; WebMD
(OPTIONAL) Uncompensated Relationships - Odyssey Biosciences; Totus Medicines
 
Kanika Arora
No Relationships to Disclose
 
Michael F. Berger
Consulting or Advisory Role - AstraZeneca; Lilly; PetDx
Patents, Royalties, Other Intellectual Property - Provisional patent pending for "Systems and Methods for Detecting Cancer via cfDNA Screening"
 
Alan Loh Ho
Stock and Other Ownership Interests - Rgenta
Honoraria - Endocrine Society; Physicans' Education Resource
Consulting or Advisory Role - AffyImmune Therapeutics; Ayala Pharmaceuticals; Cellestia Biotech; Eisai; Eisai; Elevar Therapeutics; Exelixis; ExpertConnect; InxMed; Kura Oncology; Merck; Prelude Therapeutics; Remix Therapeutics; Rgenta
Research Funding - Astellas Pharma; AstraZeneca; Ayala Pharmaceuticals; Bayer; Bayer; Bristol-Myers Squibb; Eisai; Elevar Therapeutics; Elevar Therapeutics; Genentech/Roche; Kura Oncology; Merck; Novartis
Patents, Royalties, Other Intellectual Property - LESIONAL DOSIMETRY METHODS FOR TAILORING TARGETED RADIOTHERAPY IN
 
Bob T. Li
Research Funding - Ambrx (Inst); Amgen (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Hengrui Therapeutics (Inst); Lilly (Inst); MORE Health (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Karger Publishers - Book royalty; Shanghai Jiao Tong University Press - Book royalty; US62/514,661 (Inst); US62/685,057 (Inst)
Travel, Accommodations, Expenses - Jiangsu Hengrui Medicine; MORE Health
(OPTIONAL) Uncompensated Relationships - Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Genentech; Lilly